Measurement of patient‐relevant benefits in the treatment of chronic hand eczema – a novel approach
- 16 July 2009
- journal article
- clinical trial
- Published by Wiley in Contact Dermatitis
- Vol. 61 (1), 39-45
- https://doi.org/10.1111/j.1600-0536.2009.01536.x
Abstract
The assessment of patient-relevant treatment benefit gains importance in treatment evaluation. The 'Patient Benefit Index' (PBI) is a validated instrument for the assessment of such benefits in patients with skin diseases. Patients rate the importance of specific treatment needs before treatment and benefits achieved after treatment. To date, no specific instrument for chronic hand eczema (CHE) has been published. Development and validation of a specific PBI for treatment evaluation in patients with CHE. Items reflecting disease burden and treatment needs were collected in 20 patients with CHE. Relevant items were selected by an expert panel of dermatologists, psychologists, and patients. The resulting 'Patient Benefit Index for chronic hand eczema' (PBI-HE) was validated in an open label treatment study with alitretinoin in n = 249 patients. Cronbach's alpha was 0.93. High convergent validity was demonstrated for clinical improvement and treatment success (Spearman r = 0.60-0.78, P < 0.001); 84.3% of patients reached a PBI >or= 1, indicating more than minimum patient-relevant benefit of alitretinoin. Feasibility was high, with a rate of missing data < 1%. The PBI-HE is a feasible, reliable, and valid instrument for the assessment of patient-relevant treatment benefits in CHE.Keywords
This publication has 9 references indexed in Scilit:
- The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseasesArchiv für dermatologische Forschung, 2009
- Benefit Evaluation in Vitiligo Treatment: Development and Validation of a Patient-Defined Outcome QuestionnaireDermatology, 2008
- Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trialBritish Journal of Dermatology, 2008
- Management of chronic hand eczemaContact Dermatitis, 2007
- Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costsJournal of the American Academy of Dermatology, 2006
- Therapeutischer Nutzen in der dermatologischen BehandlungDie Dermatologie, 2005
- Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczemaBritish Journal of Dermatology, 2005
- Hand Eczema in Swedish Adults – Changes in Prevalence between 1983 and 1996Journal of Investigative Dermatology, 2002
- Measuring change over time: Assessing the usefulness of evaluative instrumentsJournal of Chronic Diseases, 1987